PPARG and diabetes mellitus: However, the complicated regulatory networks involved in the pathophysiology of diabetes have not been taken into account in previously identified drugs like the insulin-sensitizing biguanide (metformin) and thiazolidinedione (rosiglitazone and pioglitazone) drugs, which are targeted to a single molecule, such as adenosine monophosphate-dependent kinase (AMPK) [2] and peroxisome proliferator-activated receptor gamma (PPARγ) [3].